Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpicilib plus Cetuximab in HNSCC
NCT06935188Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalpiciclib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Progression Free Survival Per RECIST 1.1 at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06935188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935188.